Neoadjuvant nivolumab (N) plus /- ipilimumab (I) in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC).

被引：6

作者：

Guercio, Brendan John ^{[1
]}

Pietzak, Eugene J. ^{[1
]}

Brown, Samantha ^{[1
]}

Chen, Jie-Fu ^{[1
]}

Peters, Vanessa ^{[1
]}

Regazzi, Ashley Marie ^{[1
]}

Aggen, David Henry ^{[1
]}

Donahue, Timothy F. ^{[1
]}

Goh, Alvin C. ^{[1
]}

Cha, Eugene K. ^{[1
]}

Donat, S. Machele ^{[1
]}

Dalbagni, Guido ^{[1
]}

Bochner, Bernard H. ^{[1
]}

Funt, Samuel Aaron ^{[1
]}

Bajorin, Dean F. ^{[1
]}

Iyer, Gopa ^{[1
]}

Ostrovnaya, Irina ^{[1
]}

Al-Ahmadie, Hikmat A. ^{[1
]}

Rosenberg, Jonathan E. ^{[1
]}

Teo, Min Yuen ^{[1
]}

机构：

[1] US Natl Inst Health, Conquer Canc Fdn Amer Soc Clin Oncol, Bristol Myers Squibb, Bethesda, MD USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 06期

基金：

美国国家卫生研究院;

关键词：

D O I：

10.1200/JCO.2022.40.6_suppl.498

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

498

引用

页数：3

共 50 条

[21] Cisplatin-based neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC) in patients (pts) with impaired renal function.
Koshkin, Vadim S.
Barata, Pedro C.
Zahoor, Haris
Rybicki, Lisa A.
Almassi, Nima
Redden, Alicia M.
Fergany, Amr Farouk
Kaouk, Jihad
Haber, Georges-Pascal
Stephenson, Andrew J.
Martin, Allison
Allman, Kimberly D.
Beach, Jennifer
Ornstein, Moshe Chaim
Gilligan, Timothy D.
Garcia, Jorge A.
Rini, Brian I.
Grivas, Petros
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
[22] Treatment Approaches for Cisplatin-Ineligible Patients with Invasive Bladder Cancer
David J. Einstein
Guru Sonpavde
Current Treatment Options in Oncology, 2019, 20
[23] Treatment Approaches for Cisplatin-Ineligible Patients with Invasive Bladder Cancer
Einstein, David J.
Sonpavde, Guru
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2019, 20 (02)
[24] Is neoadjuvant chemotherapy with gemcitabine plus cisplatin beneficial in patients with muscle-invasive bladder cancer?
Yafi, Faysal A.
Kassouf, Wassim
EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (06) : 747 - 752
[25] The Quest for an Ideal Neoadjuvant Systemic Therapy in Cisplatin-Ineligible Patients with Muscle-Invasive Localized Urothelial Carcinoma
Swami, Umang
Grivas, Petros
Agarwal, Neeraj
ONCOLOGIST, 2019, 24 (05): : 580 - 583
[26] Preliminary results from phase Ib/II neoadjuvant CG0070 and nivolumab (N) for cisplatin (C)-ineligible muscle invasive bladder cancer (MIBC).
Li, Roger
Spiess, Philippe E.
Sexton, Wade J.
Gilbert, Scott Michael
Poch, Michael Adam
Pow-Sang, Julio M.
Zhang, Jingsong
Dhillon, Jasreman
Thomas, Kerry
Borjas, Gustavo
Bala, Juliet
Grandi, Paola
Burke, James
Mule, James J.
Conejo-Garcia, Jose
Jain, Rohit K.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[27] KEYNOTE-905: A phase III study of cystectomy plus perioperative pembrolizumab versus cystectomy alone in cisplatin (cis)-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC)
Galsky, M.
Necchi, A.
Shore, N. D.
Witjes, F.
Nam, K.
Godwin, J. L.
Frenkl, T. L.
Plimack, E. R.
ANNALS OF ONCOLOGY, 2019, 30
[28] Randomized phase 2 umbrella study of various neoadjuvant therapies for patients with muscle-invasive urothelial carcinoma of the bladder (MIBC) who are cisplatin-ineligible or refuse cisplatin therapy and undergoing radical cystectomy (Optimus).
Necchi, Andrea
Zakharia, Yousef
Ghali, Nadeem
Smith, Michael
Hamer-Maansson, J. E.
Lindley, Anouk
Loriot, Yohann
Meeks, Joshua J.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
[29] KEYNOTE-905/EV-303: Perioperative pembrolizumab or pembrolizumab plus enfortumab vedotin (EV) and cystectomy compared to cystectomy alone in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC).
Galsky, Matt D.
Necchi, Andrea
Shore, Neal D.
Plimack, Elizabeth R.
Jia, Calvin
Sbar, Eric
Moreno, Blanca Homet
Witjes, Johannes Alfred
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
[30] Bladder preservation in adult patients with muscle-invasive bladder cancer (MIBC) who are ineligible for or refuse radical cystectomy
Rexer, Heidrun
Niegisc, Guenter
AKTUELLE UROLOGIE, 2024, 55 (01) : 24 - 25

← 1 2 3 4 5 →